Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TERT | O14746 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6533548 | 0.91 | CYP2C9 (1.00) | CYP2C9CYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL3422484 | 0.86 | CYP2C9 (0.89) | CYP2C9CYP1A2ALDH1A1 | |
| SCHEMBL9332771 | 0.82 | CYP2C9 (0.56) | CYP2C9CYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL3459786 | 0.82 | CYP1A2 (0.65) | CYP2C9CYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL729006 | 0.82 | CYP2C9 (0.68) | CYP2C9CYP1A2ALDH1A1 | |
| SCHEMBL475390 | 0.77 | CYP2C9 (0.52) | CYP2C9CYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL31097886 | 0.77 | CYP2C9 (0.51) | CYP2C9CYP1A2ALDH1A1MEN1KMT2A | |
| P-Xylene SCHEMBL3752326 | 0.76 | CYP1A2 (0.70) | CYP2C9CYP1A2ALDH1A1TSHR | |
| SCHEMBL475391 | 0.74 | CYP2C9 (0.49) | CYP2C9CYP1A2ALDH1A1LMNACYP2D6 | |
| SCHEMBL7799784 | 0.74 | CYP2C9 (0.51) | CYP2C9CYP1A2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6013679-A | REACTING HYALURONIC ACID, OR A SALT, WITH A CARBODIIMIDE TO FORM A WATER INSOLUBLE GEL IN THE ABSENCE OF A NUCLEOPHILE AND A POLYANIONIC POLYSACCHRIDE, DRYING, COMPRESSING TO FORM WATER INSOLUBLE, BIOCOMPATIBLE GEL | ANIKA RESEARCH, INC. (US) | 2000-01-11 | — | — | US | claimed |
| EP-0611774-B1 | Production of amides and peptides without racemization in the presence of catalytic amounts of a N-hydroxy-compound | HOFFMANN LA ROCHE (CH) | 1999-05-26 | — | — | EP | claimed |
| US-5750649-A | REACTING ACID AND AMINE IN PRESENCE OF CARBODIIMIDE DEHYDRATING AGENT AND N-HYDROXY COMPOUND; PEPTIDES | HOFFMANN-LA ROCHE INC. (US) | 1998-05-12 | — | — | US | claimed |
| US-5502081-A | COMPOSITIONS FOR SURGICAL AIDS FORMED FROM REACTION OF CARBODIIMIDE WITH HYALURONIC ACID | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1996-03-26 | — | — | US | claimed |
| EP-0611774-A1 | Production of amides and peptides without racemization in the presence of catalytic amounts of a N-hydroxy-compound | F. HOFFMANN-LA ROCHE AG (CH) | 1994-08-24 | — | — | EP | claimed |
| WO-1994002517-A1 | WATER-INSOLUBLE DERIVATIVES OF HYALURONIC ACID AND THEIR METHODS OF PREPARATION AND USE | ANIKA RESEARCH, INC. (US) | 1994-02-03 | — | — | WO | claimed |
| WO-2024110843-A1 | ENHANCING OLIGONUCLEOTIDE IMMUNOMODULATORY ACTIVITY THROUGH DIANOPHORE LONG-LASTING MODIFICATION: METHODS AND APPLICATIONS | SEGENA CORPORATION S.A. (UY) | 2024-05-30 | — | — | WO | disclosed |
| US-11664504-B2 | Hematin modified bilirubin oxidase cathode | CFD RESEARCH CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-20210384520-A1 | HEMATIN MODIFIED BILIRUBIN OXIDASE CATHODE | CFD RESEARCH CORPORATION | 2021-12-09 | — | — | US | disclosed |
| US-11127966-B2 | Hematin modified bilirubin oxidase cathode | CFD RESEARCH CORPORATION (US) | 2021-09-21 | — | — | US | disclosed |
| US-9950931-B2 | Cross-linked graphene networks | THE BIO NANO CENTRE LIMITED (GB) | 2018-04-24 | — | — | US | disclosed |
| EP-2822893-B1 | CROSS-LINKED GRAPHENE NETWORKS | THE BIO NANO CENTRE LTD (GB) | 2017-12-27 | — | — | EP | disclosed |
| US-9643149-B2 | Cross-linked carbon nanotube networks | THE BIO NANO CENTRE LIMITED (GB) | 2017-05-09 | — | — | US | disclosed |
| EP-0314862-A1 | Immunogenic conjugates comprising cyclosporins | SANDOZ AG (CH) | 1989-05-10 | — | — | EP | disclosed |
| US-4798840-A | Coronary-active fluorine-containing 1,4-dihydropyridines | BAYER AKTIENGESELLSCHAFT (DE) | 1989-01-17 | — | — | US | disclosed |
| EP-0290762-A1 | Cyclosporins | SANDOZ AG (CH) | 1988-11-17 | — | — | EP | disclosed |
| EP-0288758-A2 | Dihydropyridinamides, process for their preparation and their use in medicines | BAYER AG (DE) | 1988-11-02 | — | — | EP | disclosed |
| US-4556637-A | ENZYME BOUND TO A CROSSLINKED ACRYLIC POLYMER ACTIVATED BY A CARBODIIMIDE | REANAL FINOMVEGYSZERGYAR (HU) | 1985-12-03 | — | — | US | disclosed |
| EP-0089290-A1 | Conjugates of haptenes and muramyl peptides having an immunogenic activity, and compositions containing them | ANVAR Agence Nationale de Valorisation de la Recherche (FR) | 1983-09-21 | — | — | EP | disclosed |
| US-4132746-A | Synthetic elastomeric insoluble cross-linked polypentapeptide | UNIVERSITY OF ALABAMA, BIRMINGHAM MEDICAL & EDUCATION FOUNDATION (US) | 1979-01-02 | — | — | US | disclosed |